APPLICATION OF NOVEL CORONAVIRUS VACCINE PEPTIDE AND NANOEMULSION PREPARATION THEREOF IN PREVENTION OF NOVEL CORONAVIRUS WILD AND MUTANT STRAINS
Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 08. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GONG LIKUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-08, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 |
|---|
| Patentnummer: |
WO2022253193 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017397766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017397766 | ||
| 003 | DE-627 | ||
| 005 | 20230708151957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230630s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017397766 | ||
| 035 | |a (EPA)WO2022253193 | ||
| 035 | |a (EPA)84230446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GONG LIKUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a APPLICATION OF NOVEL CORONAVIRUS VACCINE PEPTIDE AND NANOEMULSION PREPARATION THEREOF IN PREVENTION OF NOVEL CORONAVIRUS WILD AND MUTANT STRAINS |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-08, Last update posted on www.tib.eu: 2023-06-29, Last updated: 2023-07-08 | ||
| 520 | |a Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a REN JIN |4 aut | |
| 700 | 0 | |a HUANG WEI |4 aut | |
| 700 | 0 | |a GAN YONG |4 aut | |
| 700 | 0 | |a ZHENG YONGTANG |4 aut | |
| 700 | 0 | |a SUN JIANHUA |4 aut | |
| 700 | 0 | |a ZHANG XINXIN |4 aut | |
| 700 | 0 | |a LONG YIRU |4 aut | |
| 700 | 0 | |a QIN QIUPING |4 aut | |
| 700 | 0 | |a LIU TINGTING |4 aut | |
| 700 | 0 | |a TANG FENG |4 aut | |
| 700 | 0 | |a YU PAN |4 aut | |
| 700 | 0 | |a MIAO YUNQIU |4 aut | |
| 700 | 0 | |a CAI YONGLONG |4 aut | |
| 700 | 0 | |a QIN MIAN |4 aut | |
| 700 | 0 | |a SONG TIANZHANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 08. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:08 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84230446/publication/WO2022253193A1?q=WO2022253193 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 08 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 08 |c 12 | ||